<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3887">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04723407</url>
  </required_header>
  <id_info>
    <org_study_id>87RI20_0062 /RICOVID19</org_study_id>
    <nct_id>NCT04723407</nct_id>
  </id_info>
  <brief_title>Assessment of the Psychological Impact of the COVID19 (SARS-CoV-2) Pandemic on Patients With Chronic Inflammatory Rheumatism</brief_title>
  <acronym>RICOVID19</acronym>
  <official_title>Assessment of the Psychological Impact of the COVID19 (SARS-CoV-2) Pandemic on Patients With Chronic Inflammatory Rheumatism According to a Management Strategy in the Rheumatology Department of Limoges University Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with chronic inflammatory rheumatism (RIC) or autoimmune diseases, rheumatoid&#xD;
      arthritis and spondyloarthritis, are regularly monitored in consultation as part of a &quot;treat&#xD;
      to target&quot; strategy with rapid adaptation of treatments to the activity of their disease.&#xD;
      according to French recommendations.&#xD;
&#xD;
      They are treated with immunosuppressive drugs: disease-modifying treatments with very often&#xD;
      methotrexate, associated with biotherapies or targeted therapies (JAK inhibitors) They can&#xD;
      also be treated transiently or over the long term with corticosteroids. These treatments&#xD;
      expose them to greater infectious risks, especially with regard to COVID19.&#xD;
&#xD;
      The objective is on the one hand to assess the impact of the Covid 19 pandemic on general&#xD;
      state of health of these patients and the evolution of their disease and on the other hand to&#xD;
      prioritize the optimal care of these patients by including in the context of maintaining the&#xD;
      pandemic reduction rules, modern telemedicine technologies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>post-traumatic stress</measure>
    <time_frame>Day 1</time_frame>
    <description>Presence or absence of post-traumatic stress disorder due to the COVID19 pandemic assessed by the Post-traumatic stress disorder Check-list version DSM-5 (PCL-5)</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">950</enrollment>
  <condition>Rheumatism</condition>
  <arm_group>
    <arm_group_label>Exposed patients</arm_group_label>
    <description>Those who had the management strategy implemented by the service during confinement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Unexposed patients</arm_group_label>
    <description>Those who could not benefit from this strategy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaires</intervention_name>
    <description>Questionnaire completion</description>
    <arm_group_label>Exposed patients</arm_group_label>
    <arm_group_label>Unexposed patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with chronic inflammatory rheumatism followed in the rheumatology department&#xD;
        of the CHU de Limoges&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All patients with chronic inflammatory rheumatism followed in the rheumatology department&#xD;
        of the CHU de Limoges.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients who object to the use of their data.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Philippe BERTIN, MD</last_name>
    <phone>0555056871</phone>
    <email>philippe.bertin@chu-limoges.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Corinne TRAPY</last_name>
    <email>corinne.trapy@chu-limoges.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>DÃ©partement de Rhumatologie</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Philippe BERTIN, MD</last_name>
      <phone>0555056871</phone>
      <email>philippe.bertin@chu-limoges.fr</email>
    </contact>
    <contact_backup>
      <last_name>Corinne TRAPY</last_name>
      <email>corinne.trappy@chu-limoges.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 22, 2021</study_first_submitted>
  <study_first_submitted_qc>January 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2021</study_first_posted>
  <last_update_submitted>January 24, 2021</last_update_submitted>
  <last_update_submitted_qc>January 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rheumatic Fever</mesh_term>
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Collagen Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

